Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

JAMA Network

This cohort study investigates the immunogenicity and safety of a third SARS-CoV-2 vaccine dose in patients with multiple sclerosis who had a weak immune

  • 1486111642236633099 Profile photo of Madelyn

    Study found a third dose of the mRNA #COVID19 vaccine in patients with #multiplesclerosis being treated with anti-CD20 therapy or fingolimod improved protective humoral immunity and is considered safe. https://t.co/QpbWXq8q2i - view on twitter